Mintz served as legal counsel to global investment firm Sixth Street in its $500 million structured term loan financing facility to Biohaven Pharmaceutical Holding Company Ltd. (Biohaven; NYSE: BHVN), a Connecticut-based biopharmaceutical company focused on the development and commercialization of therapies for debilitating neurological and neuropsychiatric diseases. The companies entered into the loan facility on August 7.
Under the terms of the loan facility, the proceeds will be used for the development, promotion, and commercial launch of Biohaven’s NURTEC ODT (rimegepant), a U.S. Food and Drug Administration (FDA)-approved acute treatment for migraine, as well as for general corporate purposes. A significant portion of the loan facility ($375 million) is available to Biohaven immediately upon closing, with the remaining committed and available pending net sales of NURTEC ODT during the first half of 2021.
The Mintz team that advised Sixth Street was led by Member and head of the firm’s Royalty Monetization Practice Richard Gervase and included Members Joanne Hawana and Paul Ricotta, and Associate John Forrest.